Indeed, for example, recent work has shown that loss of BRCA1-associated protein 1 (BAP-1), a tumor repressor, results in a dramatic decrease in H4K20me1, catalyzed by SETD8, which sensitizes tumor cells to EZH2 pharmacologic inhibition and highlights a novel therapeutic approach for BAP1-mutant malignancies [100]. Here, EZH2 is linked to neoplasm.